{"product_id":"memorial-sloan-kettering-cancer-center-state-of-the-art","title":"Memorial Sloan Kettering Cancer Center State-of-the-Art in Benign Hematology, Hemostasis, and Thrombosis 2025","description":"\u003cdiv class=\"prod-edition\"\u003e\n\u003ch3 class=\"product_title entry-title\"\u003eMemorial Sloan Kettering Cancer Center State-of-the-Art in Benign Hematology, Hemostasis, and Thrombosis 2025\u003c\/h3\u003e\n\u003cstrong\u003e+ Include: 11 videos + 12 pdfs, size: 6.4 GB\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Target Audience: general medicine, hematology\/oncology, fellows, hospitalists, nocturnists, emergency medicine providers\u003c\/strong\u003e\n\u003cbr\u003e\u003cstrong\u003e+ Information:\u003c\/strong\u003e\n\u003cbr\u003e\u003cdiv class=\"activitysectionbold\"\u003eDate \u0026amp; Location Sunday, October 26, 2025, 9:00 AM – 5:30 PM, Zuckerman Research Center, 417 East 68th Street, New York, NY\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cem\u003eSpecialties\u003c\/em\u003e – Emergency Medicine, Hematology, Hematopathology, Hospitalist, Immunotherapy, Internal Medicine, Interventional Radiology, Leukemia, Nurse Practitioner, Oncology and Hematology, Physician Assistant, Pulmonary Medicine, Transfusion Medicine\u003c\/div\u003e\n\u003cdiv\u003e\u003c\/div\u003e\n\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eOverview\u003c\/strong\u003e\u003c\/div\u003e\n\u003cbr\u003eThis one-day symposium will provide a state-of-the-art update in benign hematology, with a particular focus on emerging therapeutic strategies. The program will feature in-depth presentations by expert faculty, with dedicated time for interactive discussion and Q\u0026amp;A.\u003cbr\u003e\u003cbr\u003eNow in its 10th year, the 2025 program will focus on:\u003cbr\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eComplex management scenarios in hemostasis and thrombosis,\u003c\/strong\u003e including stroke in cancer, cardiac thrombosis, and thrombotic risk in acute lymphoblastic leukemia (ALL)\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eAdvances in management of hemolytic anemias, \u003c\/strong\u003ewith a focus on the therapeutic management of hereditary anemia, paroxysmal nocturnal hemoglobinuria (PNH), cold agglutinin disease, and other complement-mediated hemolytic disorders\u003c\/li\u003e\n\u003cli\u003e\u003cstrong\u003eHematologic complications related to cellular therapies and immunotherapies\u003c\/strong\u003e\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNovel treatment approaches,\u003c\/strong\u003e including factor XI inhibitors and anticomplement agents, and the unique challenges associated with their use\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cbr\u003eThe\u003cstrong\u003e target audience\u003c\/strong\u003e for this symposium includes general medicine, hematology\/oncology, fellows, hospitalists, nocturnists, emergency medicine providers, advanced practice providers and other healthcare professionals who manage and treat thrombotic and bleeding disorders. Please note that this symposium will be offered \u003cstrong\u003eexclusively in person\u003c\/strong\u003e; a virtual attendance option will not be available.\u003cbr\u003e\u003cbr\u003eFollowing the symposium, registrants will receive \u003cstrong\u003eaccess to an online syllabus\u003c\/strong\u003e featuring select PDF slides from faculty presentations and recorded session videos.\u003cbr\u003e\u003cdiv class=\"activitysectionbold\"\u003e\u003cstrong\u003eObjectives\u003c\/strong\u003e\u003c\/div\u003e\n\u003cdiv\u003eAt the conclusion of this symposium, attendees will be able to:\u003c\/div\u003e\n\u003col\u003e\n\u003cli\u003eDiscuss current updates in the management of challenging benign hematologic conditions, with a focus on emerging therapeutics\u003c\/li\u003e\n\u003cli\u003eAnalyze current data and discuss emerging FXI inhibitors\u003c\/li\u003e\n\u003cli\u003eDescribe anticomplement therapies\u003c\/li\u003e\n\u003cli\u003eRecognize the challenges in diagnosis and management of hematologic complications of immunotherapy\u003c\/li\u003e\n\u003c\/ol\u003e\n\u003cbr\u003e \u003cbr\u003e\u003cbr\u003e\u003cstrong\u003e+ Topics:\u003c\/strong\u003e\n\u003cbr\u003e\u003ch3 class=\"boxAgendaTitle\"\u003eSunday, October 26, 2025\u003c\/h3\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"12u\"\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eEmerging Data on Factor XI Inhibitors\u003c\/strong\u003e\u003cbr\u003e9:00AM – 9:30AM\u003cbr\u003eJeffrey Zwicker, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eCryptogenic Stroke and Cancer\u003c\/strong\u003e\u003cbr\u003e9:30AM – 10:00AM\u003cbr\u003eBabak Navi, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eBenefits of Extended Post-op Thromboprophylaxis in the Era of Robotic Surgery\u003c\/strong\u003e\u003cbr\u003e11:00AM – 11:30AM\u003cbr\u003eMarc Carrier, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eThrombotic Risk in Acute Lymphoblastic Leukemia\u003c\/strong\u003e\u003cbr\u003e11:30AM – 12:00PM\u003cbr\u003eAvi Leader, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eInherited Hemolytic Anemias: Scientific Advances in Therapeutics\u003c\/strong\u003e\u003cbr\u003e1:30PM – 2:00PM\u003cbr\u003eMohandas Narla, DSc\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eAnticomplement Therapy for Paroxysmal Nocturnal Hemoglobinuria\u003c\/strong\u003e\u003cbr\u003e2:00PM – 2:30PM\u003cbr\u003edavid araten, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eManagement of Cold Agglutinin Disease\u003c\/strong\u003e\u003cbr\u003e2:30PM – 3:00PM\u003cbr\u003eRekha Parameswaran, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eHLH-like Toxicities Secondary to Cancer Immunotherapy\u003c\/strong\u003e\u003cbr\u003e3:30PM – 4:00PM\u003cbr\u003eWilliam Johnson, DO\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eThrombosis Related to Immune Therapy\u003c\/strong\u003e\u003cbr\u003e4:00PM – 4:30PM\u003cbr\u003eJodi Mones, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eUpdates in Immune Thrombocytopenia\u003c\/strong\u003e\u003cbr\u003e4:30PM – 5:00PM\u003cbr\u003eCy R Wilkins, MD\u003c\/div\u003e\n\u003cdiv class=\"2u\"\u003e\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"boxAgenda agendaBlue\"\u003e\n\u003cdiv class=\"row 50%\"\u003e\n\u003cdiv class=\"10u\"\u003e\n\u003cstrong\u003eTransplant-Associated Thrombotic Microangiopathy\u003c\/strong\u003e\u003cbr\u003e5:00PM – 5:30PM\u003cbr\u003eMohammad Alhomoud, MBBS\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"meducours","offers":[{"title":"Default Title","offer_id":42954522493026,"sku":"MED-AMB05250","price":40.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0662\/9549\/6802\/files\/Memorial-Sloan-Kettering-Cancer-Center-State-of-the-Art-in-Benign-Hematology-Hemostasis-and-Thrombosis-2025.jpg?v=1779378822","url":"https:\/\/meducourse.com\/products\/memorial-sloan-kettering-cancer-center-state-of-the-art","provider":"Meducourse","version":"1.0","type":"link"}